Transnasal Sphenopalatine Ganglion Block for Postoperative Pain and Recovery in Tonsillectomy (TONwoPA)

Condition(s) studied

Investigational drug(s) / intervention(s)

Transnasal Transmucosal Sphenopalatine Ganglion Block: Before the start of surgery, a preemptive transnasal transmucosal sphenopalatine ganglion block will be performed using cotton-tipped applicators. The assigned solutions will be administered via the applicators according to group allocation.

Lidocaine %5: Transnasal Transmucosal Sphenopalatine Ganglion Block with Lidocaine %5

Saline (0.9% NaCl): Transnasal Transmucosal Sphenopalatine Ganglion Block with Saline (0.9% NaCl)

Study summary

The aim of this clinical trial is to evaluate the effectiveness of transnasal transmucosal sphenopalatine ganglion block in reducing post-tonsillectomy pain. The study also investigates its impact on rescue analgesic requirements and postoperative recovery by comparing 5% lidocaine with placebo.

Participants will receive a transnasal transmucosal sphenopalatine ganglion block with either 5% lidocaine or placebo (saline). Postoperative pain levels and opioid consumption will be monitored during the first 24 hours after surgery. In addition, length of hospital stay, the occurrence of primary and secondary post-tonsillectomy hemorrhage up to 14 days, unplanned hospital readmissions after discharge, and patient satisfaction on postoperative day 14 will be assessed.

Eligibility

Primary outcome measure(s)

• Postoperative NRS Score and Opioid Consumption — Postoperative 1. 2. 4. 8. 16. and 24. Hours
  The NRS (Numeric Rating Scale) score will be used to assess the pain during follow ups. Scale: 0 (no pain) to 10 (worst pain). Higher scores on the NRS indicate worse pain.

Trial sites (1)

More Ankara University trials in Turkey

Other trials for the same condition